WeightWatchers Stock Drops 12% After Eli Lilly Launches DTC Weight-Loss Drug Service
By Will Feuer
Shares of WW International, also known as WeightWatchers, fell after the pharmaceutical company Eli Lilly started a new online service offering telehealth prescriptions and direct home delivery of its new anti-obesity drug Zepbound.
The stock fell 12% to $6.77 in afternoon trading, the shares are up about 55% in the past 12 months.
WW has been pushing into telehealth in a bid to ride the wave of weight-loss drugs. Last year, the company bought telehealth firm Sequence for $106 million.
Analysts at DA Davidson said Lilly's telehealth platform, called LillyDirect, will likely have an advantage over rivals while supply of the weight-loss drugs is scarce. Once production ramps up, though, "the winners and losers in this space will be determined by who can provide the best service," the analysts said.
The new Lilly service also hit shares of other telehealth companies, including Hims & Hers Health, which traded down about 7%. Shares of LifeMD fell about 33%.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
January 04, 2024 16:15 ET (21:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst